Submitted:
01 October 2023
Posted:
04 October 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Retrieving the Compounds
2.2. Inducing genes of the PCs
2.3. Enrichment analysis
2.4. Protein-protein interactions
2.5. Molecular docking
2.6. Molecular dynamics simulations and MMGBSA
3. Discussion
4. Materials and Methods
4.1. Retrieving the Compounds
4.2. Inducing genes of the PCs
4.3. Enrichment analysis
4.4. Protein-protein interactions
3.5. Molecular docking
3.6. Molecular dynamics simulations and MMGBSA
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Harvey, A.L. Natural products in drug discovery. Drug Discovery Today, 2008, 13, 894–901. [Google Scholar] [CrossRef] [PubMed]
- Mathur, S., Hoskins, C. Drug development: Lessons from nature. Biomedical Reports, 2017, 6, 612–614. [CrossRef] [PubMed]
- Kumari, S., Seth, A., Sharma, S., Attri, C. A holistic overview of different species of Potentilla a medicinally important plant along with their pharmaceutical significance: A review. Journal of Herbal Medicine, 2021, 29, 100460. [CrossRef]
- Tomczyk, M., Pleszczyńska, M., Wiater, A. Variation in total polyphenolics contents of aerial parts of Potentilla species and their anticariogenic activity. Molecules (Basel, Switzerland), 2010, 15, 4639–4651. [CrossRef] [PubMed]
- Kumari, S., Seth, A., Sharma, S., Attri, C. A holistic overview of different species of Potentilla a medicinally important plant along with their pharmaceutical significance: A review. Journal of Herbal Medicine, 2021, 29, 100460. [CrossRef]
- Tomczyk, M., Paduch, R., Wiater, A., Pleszczyńska, M., Kandefer-Szerszeń, M., Szczodrak, J. The influence of aqueous extracts of selected Potentilla species on normal human colon cells. Acta Poloniae Pharmaceutica, 2013, 70, 523–531.
- Tomczyk, M., Leszczyńska, K., Jakoniuk, P. Antimicrobial activity of Potentilla species. Fitoterapia, 2008, 79, 592–594. [CrossRef]
- Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J. T., Harris, M.A., Hill, D.P., Issel-Tarver, L., Kasarskis, A., Lewis, S., Matese, J.C., Richardson, J.E., Ringwald, M., Rubin, G. M., Sherlock, G. Gene Ontology: Tool for the unification of biology. Nature Genetics, 2000, 25, 25–29. [CrossRef]
- Liu, L.-L.; Zhao, H.; Ma, T.-F.; Ge, F.; Chen, C.-S.; Zhang, Y.-P. Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection. PloS One 2015, 10, e0117058. [Google Scholar] [CrossRef]
- Fu, J., Bian, L., Zhao, L., Dong, Z., Gao, X., Luan, H., Sun, Y., Song, H. Identification of genes for normalization of quantitative real-time PCR data in ovarian tissues. Acta Biochimica Et Biophysica Sinica, 2010, 42, 568–574. [CrossRef]
- Cartwright, T., Perkins, N.D., Wilson, C. NFKB1: A suppressor of inflammation, ageing and cancer. The FEBS Journal, 2016, 283, 1812–1822. [CrossRef] [PubMed]
- Li, J., Lei, W.-T., Zhang, P., Rapaport, F., Seeleuthner, Y., Lyu, B., Asano, T., Rosain, J., Hammadi, B., Zhang, Y., Pelham, S. J., Spaan, A.N., Migaud, M., Hum, D., Bigio, B., Chrabieh, M., Béziat, V., Bustamante, J., Zhang, S.-Y., Boisson, B. Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency. Journal of Experimental Medicine, 2016, 218, e20210566. [CrossRef]
- Guo, Q., Zhu, Q., Zhang, T., Qu, Q., Cheang, I., Liao, S., Chen, M., Zhu, X., Shi, M., Li, X. Integrated bioinformatic analysis reveals immune molecular markers and potential drugs for diabetic cardiomyopathy. Frontiers in Endocrinology, 2022, 13, 933635. [CrossRef] [PubMed]
- Gaptulbarova, K.A., Tsyganov, M.M., Pevzner, A.M., Ibragimova, M.K., Litviakov, N.V. NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer. Experimental oncology, 2020, 42, 263–269. [CrossRef]
- Weinmann, D., Mueller, M., Walzer, S.M., Hobusch, G.M., Lass, R., Gahleitner, C., Viernstein, H., Windhager, R., Toegel, S. Brazilin blocks catabolic processes in human osteoarthritic chondrocytes via inhibition of NFKB1/p50: BRAZILIN BLOCKS CATABOLIC PROCESSES VIA INHIBITION OF NFKB1/p50. Journal of Orthopaedic Research, 2018, 36, 2431–2438. [CrossRef]
- Reikvam, H. Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. Cells, 2020, 9, 1677. [Google Scholar] [CrossRef]
- Damineni, S., Rao, V.R., Kumar, S., Ravuri, R.R., Kagitha, S., Dunna, N.R., Digumarthi, R., Satti, V. Germline mutations of TP53 gene in breast cancer. Tumor Biology, 2014, 35, 9219–9227. [CrossRef]
- Hassin, O., Oren, M. Drugging p53 in cancer: One protein, many targets. Nature Reviews Drug Discovery, 2023, 22, 127–144. [CrossRef]
- Nayak, S.K., Khatik, G.L., Narang, R., Monga, V., Chopra, H.K. P53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents. Current Cancer Drug Targets, 2018, 18, 749–772. [CrossRef]
- Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., Brown, P.H. Molecularly targeted therapies for p53-mutant cancers. Cellular and Molecular Life Sciences, 2017, 74, 4171–4187. [CrossRef]
- Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B.A., Thiessen, P.A., Yu, B., Zaslavsky, L., Zhang, J., Bolton, E.E. PubChem 2023 update. Nucleic Acids Research, 2023, 51, 1373–1380. [CrossRef]
- Lagunin, A., Ivanov, S., Rudik, A., Filimonov, D., Poroikov, V. DIGEP-Pred: Web service for in silico prediction of drug-induced gene expression profiles based on structural formula. Bioinformatics, 2013, 29, 2062–2063. [CrossRef] [PubMed]
- Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S.L., Jagodnik, K.M., Lachmann, A., McDermott, M.G., Monteiro, C.D., Gundersen, G.W., Ma’ayan, A. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research, 2016, 44, 90–97. [CrossRef]
- Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A.L., Fang, T., Doncheva, N.T., Pyysalo, S., Bork, P., Jensen, L.J., von Mering, C. The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Research, 2023, 51, 638–646. [CrossRef]
- Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 2003, 13, 2498–2504. [CrossRef] [PubMed]
- Praveen, M., Morales-Bayuelo, A. Drug Designing against VP4, VP7 and NSP4 of Rotavirus Proteins – Insilico studies. Moroccan Journal of Chemistry, 2023, 11, 729–741. [CrossRef]
- Stroud, J.C., Oltman, A., Han, A., Bates, D.L., Chen, L. Structural Basis of HIV-1 Activation by NF-κB—A Higher-Order Complex of p50:RelA Bound to the HIV-1 LTR. Journal of Molecular Biology, 2009, 393, 98–112. [CrossRef]
- Wright, L., Barril, X., Dymock, B., Sheridan, L., Surgenor, A., Beswick, M., Drysdale, M., Collier, A., Massey, A., Davies, N., Fink, A., Fromont, C., Aherne, W., Boxall, K., Sharp, S., Workman, P., Hubbard, R.E. Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms. Chemistry & Biology, 2004, 11, 775–785. [CrossRef]
- O’Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R. Open Babel: An open chemical toolbox. Journal of Cheminformatics, 2011, 3, 33. [CrossRef]
- Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 2009, 30, 2785–2791. [CrossRef]
- Trott, O., Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2009. [CrossRef]
- Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A., Case, D.A. Development and testing of a general amber force field. Journal of Computational Chemistry, 2004, 25, 1157–1174. [CrossRef] [PubMed]
- Pettersen, E.F., Goddard, T.D., Huang, C.C., Meng, E.C., Couch, G.S., Croll, T.., Morris, J.H., Ferrin, T.E. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Science: A Publication of the Protein Society, 2021, 30, 70–82. [CrossRef]
- Tian, C., Kasavajhala, K., Belfon, K.A.A., Raguette, L., Huang, H., Migues, A.N., Bickel, J., Wang, Y., Pincay, J., Wu, Q., Simmerling, C. ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution. Journal of Chemical Theory and Computation, 2020, 16, 528–552. [CrossRef] [PubMed]
- Genheden, S., Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 2015, 10, 449–461. [CrossRef]
- Turner, PJ. XMGRACE, Version 5.1.19; Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology: Beaverton, OR, 2005. [Google Scholar]
- R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2018. Available online at https://www.R-project.org/.










| Descriptors | MR | MS | NR | NS |
|---|---|---|---|---|
| BP | nucleic acid-templated transcription positive regulation, | DNA-templated transcription regulation, Nucleic acid-templated transcription positive regulation |
Nucleic acid-templated transcription positive regulation, | Nucleic acid-templated transcription positive regulation |
| MF | Protein homodimerization activity, | Protein Serine/Threonine Phosphatase activity | DNA binding, Protein Homodimerization Activity, |
DNA-Binding transcription activator activity, Protein Serine/Threonine Phosphatase activity, Oxidoreductase activity |
| CC | Intracellular membrane-bounded organelle, Nucleus, secretory granule lumen |
Nucleus, Azurophil granule lumen | Intracellular membrane-bounded organelle, Nucleus |
Intracellular organelle lumen, Endoplasmic reticulum lumen, Secretory granule lumen |
| Pathways | Vegfa-Vegfr2 signalling pathway, Leptin signalling pathway, Micro-RNAs in cardiomyocyte hypertrophy, B-cell receptor signalling pathway | Nuclear receptors meta-pathway, Osteoblast differentiation, Vitamin-D receptor pathway | Nuclear receptors meta-pathway, Vitamin-D receptor pathway | Common pathways underlying drug addiction, Melanoma, pyrimidine metabolism |
| Diseases | Neoplasm metastasis, Liver carcinoma, Mammary neoplasms, Melanoma | Neoplasm metastasis, Breast carcinoma, Prostate malignant neoplasm | Neoplasm metastasis, Liver carcinoma |
Breast carcinoma, Breast neoplasm malignant, Neoplasm metastasis |
| Drugs | Aprindine, Domperidone Trifluoperazine, Pitolisant, Cyproheptadine, Pimozide, Brompheniramine Buprenorphine, Lidoflazine, Chlorambucil |
Mefenamic Acid, Diclofenac, Flufenamic Acid, Quercetin Mezlocillin,,Hydrochlorothiazide Hydroxycarbamide Bendroflumethiazide Benzthiazide, Chlorambucil |
Bezafibrate, Rosiglitazone Stearic Acid, Dodecanoic Acid, Gamolenic Acid, Aprindine, Caffeine, Eicosapentaenoic Acid, Linolenic Acid, Mefenamic Acid |
Stearic Acid, Epalrestat Dodecanoic Acid, Gamolenic Acid, Vemurafenib, Bezafibrate, Gemfibrozil, Linolenic Acid, Aprindine, Eicosapentaenoic Acid |
| Induced genes used | Proteins | Network topological parameters | ||||
| DC | Avg short. path leng. | CC | C. cen | BC | ||
| MR | HSPCB | 15 | 3.02 | 0.18 | 0.33 | 0.18 |
| NFKB1 | 15 | 2.85 | 0.25 | 0.34 | 0.33 | |
| MS | TP53 | 25 | 1.87 | 0.15 | 0.53 | 0.56 |
| NR | TP53 | 20 | 2.32 | 0.16 | 0.42 | 0.58 |
| NS | TP53 | 25 | 1.75 | 0.17 | 0.57 | 0.59 |
| Complex |
B.A. (kcal /mol) |
Hydrogen Bonds | Hydrophobic bonds | Other bonds | |||||
| Proteins | PCs | CHB | π-Alkyl | Alkyl | π - π Stacked | π - π T Shaped | π -Sigma | ||
| p53 | 1b | -8.6 | ASer1503 |
4ATrp1495, ATyr1502, 2APhe1519, ATyr1523, 3BTrp1495, 3BTyr1502, 2BPhe1519, BTyr1523 |
2BMet1584 | - | - | - | - |
| 2a | -8.0 | - |
2ATrp1495, 2ATyr1502, 2APhe1519, 2BTrp1495, BTyr1502, 2BPhe1519, BTyr1523 |
AMet1584 | - | - | - | - | |
| HSP | 3a | -9.6 | - | APhe138, Aval150 | AMet98, 2ALeu107, AAla111 | APhe138 | - | AMet98 | AMet98 |
| 4a | -8.7 | - | 3APhe138, 2ATrp162, AMet98, ALeu107 | 2AVal186, 2AMet98, AVal150, ALeu107 | APhe138 | - | 2Trp162 | - | |
| 4c | -8.2 | 2ATrp162 | APhe22, APhe170, 2ALeu107, AMet98, AVal150 |
AIle26 | 2APhe138 | ATyr139, 2ATrp162 | - | - | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).